News

HepaLife said that its subsidiary, Alliqua BioMedical (Alliqua), recently retained Jeiven Pharmaceutical Consulting (Jeiven) to assist it in this new product development. Through this partnership, Alliqua intends to

Talecris Biotherapeutics claims that Prolastin-C is more concentrated and purified formulation of Prolastin, the only approved alpha1-augmentation therapy in Canada. Prolastin-C and Prolastin are indicated for chronic augmentation

The grant to GTx comprises separate payments of $244,000 for each of five cancer and cancer supportive care research and development programs. Gtx CEO Mitchell Steiner said that

Enzon Pharma has posted a net loss of $8.35m for the third quarter 2010, compared to net income of $133,000 for the comparable period in 2009. The company’s

CeNeRx said that these positive results further confirm the good safety profile demonstrated by TriRima in Phase I studies and set the stage for a Phase II clinical

Pursuant to the stock purchase agreement, Cambrex is expected to acquire the remaining 49% in early 2016 at a value based on a weighted combination of a multiple

Silenor is approved for use in people with chronic (long-term) or transient (short-term) insomnia characterised by difficulty with sleep maintenance. According to Somaxon, Silenor can be used for

OncoMed’s lead candidate, OMP-21M18, is currently in Phase Ib clinical trials. OncoMed’s pipeline also includes several preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed Pharma

Desloratadine tablets 5mg are the generic version of Schering-Plough’s Clarinex tablets, 5mg. Clarinex, a prescription medication, treats year-round allergy symptoms and ongoing hives of unknown cause, in adults